Whitehawk Therapeutics (NASDAQ: WHWK) insider transactions
In the twelve months to 10 November 2026, executives and directors of Whitehawk Therapeutics reported 14 open-market sales of 705,358 shares ($2.6m) and 0 open-market purchases, by 3 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 14 May 2026 | Dalal Anupam | Director | Grant or award | +1,275,510 | $3.92 | 4,685,912 | Form 4 |
| 14 May 2026 | Castelein Caley | Director | Grant or award | +255,102 | $3.92 | 274,796 | Form 4 |
| 14 May 2026 | Giacobello Scott M. | Chief Financial Officer | Grant or award | +38,265 | $3.92 | 333,489 | Form 4 |
| 14 May 2026 | Ball Bryan | See remarks | Grant or award | +51,020 | $3.92 | 448,126 | Form 4 |
| 14 May 2026 | Dugan Margaret | Chief Medical Officer | Grant or award | +19,132 | $3.92 | 19,132 | Form 4 |
| 14 May 2026 | Lennon David James | Chief Executive Officer | Grant or award | +51,021 | $3.92 | 569,643 | Form 4 |
| 16 April 2026 | Giacobello Scott M. | Chief Financial Officer | Open-market sale | −141,600 | $4.13 | 295,224 | Form 4 |
| 15 April 2026 | Giacobello Scott M. | Chief Financial Officer | Open-market sale | −77,000 | $3.86 | 436,824 | Form 4 |
| 14 April 2026 | Ball Bryan | See remarks | Open-market sale | −92,460 | $3.64 | 397,106 | Form 4 |
| 13 April 2026 | Ball Bryan | See remarks | Open-market sale | −26,389 | $3.46 | 489,566 | Form 4 |
| 10 April 2026 | Ball Bryan | See remarks | Open-market sale | −6,596 | $3.43 | 515,955 | Form 4 |
| 9 April 2026 | Ball Bryan | See remarks | Open-market sale | −50,000 | $3.57 | 522,551 | Form 4 |
| 9 April 2026 | Lennon David James | Chief Executive Officer | Open-market sale | −14,500 | $3.38 | 518,622 | Form 4 |
| 8 April 2026 | Lennon David James | Chief Executive Officer | Open-market sale | −63,945 | $3.40 | 533,122 | Form 4 |
| 7 April 2026 | Lennon David James | Chief Executive Officer | Open-market sale | −94,087 | $3.43 | 597,067 | Form 4 |
| 6 April 2026 | Lennon David James | Chief Executive Officer | Open-market sale | −102,395 | $3.51 | 691,154 | Form 4 |
| 2 April 2026 | Lennon David James | Chief Executive Officer | Open-market sale | −26,858 | $3.48 | 793,549 | Form 4 |
| 1 April 2026 | Giacobello Scott M. | Chief Financial Officer | Option exercise | +473,902 | — | 502,002 | Form 4 |
| 1 April 2026 | Ball Bryan | See remarks | Option exercise | +366,532 | — | 572,551 | Form 4 |
| 1 April 2026 | Lennon David James | Chief Executive Officer | Option exercise | +775,828 | — | 820,407 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Whitehawk Therapeutics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.